CIPLA1,374.00

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.11L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation1,051.01,107.01,253.0
+ Finance Costs89.962.054.4
+ Interest Income-219.6-264.4-228.6
+ Fair Value (Gains) / Losses-222.0-234.6-128.1
+ Share-based Payments46.247.359.1
+ Unrealised FX (Gain) / Loss-22.8-13.9-103.3
+ Other Non-cash Items4.7-2.04.9
+ Other — Cash Effects are Investing / Financing-86.6-183.8-383.5
+ Other Reconciling Items194.80.00.0
Changes in Working Capital
+ Inventories-61.9-322.5-642.4
+ Trade Receivables — Current-907.0-801.9465.3
+ Other Current Assets0.00.0-701.2
+ Trade Payables — Current162.7458.9252.6
+ Other Current Liabilities0.00.0400.5
Cash from Operating Activities
Profit Before Tax (per I/S)5,701.96,820.85,223.64,535.6
+ Total Adjustments (incl. Working Capital)29.5-147.7302.6
Cash from Operations (pre-tax)5,731.46,673.15,526.2
+ Income Taxes Paid1,597.51,668.11,586.2
Cash from Operating Activities4,133.95,005.03,940.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)1,098.31,162.21,599.3
+ Acq of Intangible Assets251.1386.01,480.0
+ Disp of Fixed Assets34.224.923.6
+ Disp of Intangible Assets0.08.644.1
+ Acq of Other Long-term Assets6.017.817.4
+ Disp of Other Long-term Assets0.60.00.0
+ Purchase of Investments (Equity / Debt)42.030.615.6
+ Acq of Subsidiaries / Businesses (net)300.9205.1110.7
+ Disp of Subsidiaries / Businesses (net)120.40.00.0
+ Loans & Advances Made8.726.80.0
+ Government Grants Received33.60.00.0
+ Interest Received — Investing208.2260.2222.9
+ Other Inflows / (Outflows) — Investing-1,678.1-2,156.2606.3
Cash from Investing Activities-2,988.0-3,691.1-2,326.1
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.10.0
+ Proceeds from Borrowings0.012.0187.8
+ Repayment of Borrowings300.598.00.0
+ Payment of Lease Liabilities77.080.2107.8
+ Interest Paid64.836.437.0
+ Dividends Paid686.21,049.81,292.4
+ Other Inflows / (Outflows) — Financing-72.0-40.415.8
Cash from Financing Activities-1,200.4-1,292.8-1,233.7
Net Changes in Cash (pre-FX)-54.621.1380.2
+ Effect of FX Rate Changes on Cash5.69.392.5
Net Changes in Cash-49.030.3472.7
Closing Cash512.3542.71,015.4
Reference Items
EBITDA6,291.17,127.95,882.95,297.1
EBITDA Margin %24.4125.8720.8918.70
Free Cash Flow (CFO − Capex)2,784.63,456.8860.7860.7
Free Cash Flow to Equity3,265.5989.6
Free Cash Flow per Basic Share34.4742.7910.6510.65
Price to Free Cash Flow128.95
Cash Flow to Net Income1.000.951.02
Cash Paid for Taxes1,597.51,668.11,586.2
Cash Paid for Interest64.836.437.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.